PCYTE
PharmaCyte exchanges warrants for shares and extends maturity
PharmaCyte Biotech will exchange 851,304 warrants for 4,982,272 shares and has agreed to extend the Series H preferred stock maturity. The extension was secured via the consent of the holder, who controls a majority of the Series H stock.